AB-001

AB-001 is a synthetic cannabinoid that was discovered by the team at the pharmaceutical company, Abbott Laboratories. It is a full agonist of the CB₁ receptor, which is found in the brain and central nervous system. This receptor is one of the two main types of cannabinoid receptors in the body, the other being the CB₂ receptor.

Chemistry[edit | edit source]

AB-001 is a member of the amide class of cannabinoids, which are known for their potent activity at the CB₁ receptor. The chemical structure of AB-001 includes a naphthoyl group, which is a common feature of many synthetic cannabinoids. This group is attached to an aminoalkylindazole group, which is a unique feature of AB-001 and a few other synthetic cannabinoids.

Chemical structure of AB-001

Pharmacology[edit | edit source]

AB-001 acts as a full agonist at the CB₁ receptor, meaning it can fully activate this receptor. This is in contrast to partial agonists, which can only partially activate the receptor. The activity of AB-001 at the CB₁ receptor is believed to be responsible for its psychoactive effects.

Effects[edit | edit source]

The effects of AB-001 are similar to those of tetrahydrocannabinol (THC), the main psychoactive compound in cannabis. These effects can include relaxation, euphoria, and altered perception. However, as a synthetic cannabinoid, AB-001 can also have additional effects not seen with natural cannabinoids. These can include increased heart rate, anxiety, and in some cases, severe psychotic episodes.

Legal Status[edit | edit source]

The legal status of AB-001 varies by country. In many places, it is classified as a controlled substance due to its psychoactive effects and potential for abuse. However, in some countries, it is legal to possess and use AB-001 for research purposes.